Ldl Cholesterol
Alirocumab, evinacumab confer LDL benefit in homozygous familial hypercholesterolemia
FDA approves bempedoic acid/ezetimibe for LDL lowering in ASCVD, HeFH
ODYSSEY OUTCOMES: LDL reduction with alirocumab sustained at 3 years
Gestational diabetes exposure tied to higher cholesterol, BP in children
ORION-10
ORION-9: Inclisiran safely lowers LDL up to 50% in familial hypercholesterolemia
PHILADELPHIA — Patients with heterozygous familial hypercholesterolemia who were treated with inclisiran had reductions in LDL at 510 days and at an average of the period between 90 days and 540 days independent of their underlying genotype, according to results of the ORION-9 trial presented at the American Heart Association Scientific Sessions.
Lower LDL target beneficial after stroke
PHILADELPHIA — Among patients with signs of atherosclerosis following stroke or transient ischemic attack, those who achieved a target LDL level of less than 70 mg/dL had lower risk for subsequent CV events than patients achieving LDL levels between 90 and 110 mg/dL, according to findings presented at the American Heart Association Scientific Sessions.
Cholesterol increases from Ocaliva for NASH resolve after discontinuation
Top 10 takeaways from lipid management guidelines
CHICAGO — The 2018 Guideline on the Management of Blood Cholesterol, published by the American College of Cardiology and the American Heart Association in collaboration with other societies, offered a number of pointers for clinicians to diagnose, treat and manage patients with elevated cholesterol.